This page contains a Flash digital edition of a book.
« INDUSTRY NEWS


these results hurts not only the company’s stockholders; it impedes development of an important experimental therapeutic that could save thousands of lives in West Africa.”


Equels said, “This recent study is breakthrough information regarding Ebola therapy. The US Army scientists challenged mice with a mouse- adapted Ebola virus. 100% of the Ampligen® treated mice at the lowest dose of 6 mg/kg survived the 21-day course of the experiment. However, the placebo group challenged with Ebola all died within seven days. Ampligen activates the innate immunity inhibited by the Ebola virus and is relatively insensitive to viral mutational drift, which remains a potential problem for developmental therapeutics that are dependent on invariant targets of viral protein structure. No other host immune-based experimental therapy, that we are aware of, has achieved to date similar results in animal experimentation against the Ebola virus.


Further, Ampligen® has an extensive long-term


safety record in humans derived from our clinical work. The safety profi le is appropriate given the high and rapid mortality rates from Ebola. Unlike other experimental therapies, a stockpile supply of the experimental therapeutic Ampligen® is available.


Hemispherx believes erroneous short seller rhetoric cannot be without consequence in the biotech industry.


False statements such as


Feuerstein’s must, at a minimum, be corrected publicly. “Mr. Feuerstein maligned this important discovery by choosing to focus on falsely discrediting this information and even questioning the collaboration of Hemispherx’s with USAMRIID,” said Equels. “Our collaboration with USAMRIID was centered solely on conducting these Ebola effi cacy tests, in vitro and in vivo, in their independent government laboratory. The now publicly posted report is irrefutable proof of the collaboration between USAMRIID and Hemispherx.


the positive results obtained in this study.


It is also irrefutable proof of These results compel


Hemispherx to move forward its experimental therapeutic Ampligen® in the fi ght against this dread disease plaguing West Africa and to continue to work diligently with the Food and Drug Administration (FDA) and other international organizations committed to the eff ort to mitigate the ongoing morbidity and mortality of Ebola.”


Collaboration between AYOXXA and Singapore Eye Research Institute


Validation of new protein multiplexing technology platform in the ophthalmic domain


AYOXXA, an international biotech company with headquarters in Cologne, has signed an agreement with the Singapore Eye Research Institute (SERI), one of the leading international eye research institutes. AYOXXA and SERI will work together on validating the company’s multiplexing technology platform for protein biomarker detection, as part of an expanded collaboration for developing ophthalmic diagnostic tools.


“We are pleased to start this collaboration with such a prestigious research institute like SERI,” said Michael Rasche, Corporate Vice President Global Commercial Operations of AYOXXA Biosystems GmbH. “By gaining access to very low-volume samples from the eye we can prove the benefi ts of our new protein multiplex technology beyond


the research segment in clinical settings. We want to closely work with SERI in the ophthalmology space and potentially use our technology as new diagnostic application in the treatment of age-related macular degeneration (AMD).”


“SERI has had a long and broad history of working with large and mid- size pharmaceutical and ophthalmic companies, and we are now keen to expand our collaboration scope to working with promising start-up companies from around the world, be it biotech, diagnostics or device companies, with our goal of positioning Singapore as one of the world hubs for innovative technology development in ophthalmology” said Prof. Tin Aung, Executive Director of SERI. ”The partnership with AYOXXA can potentially enable the co-development of a range of ophthalmic diagnostic tools, beginning with AMD. Having a validated diagnostic platform can potentially help better assess patients and more objectively steer their treatment. It can also potentially assist in the development of new treatments.”


Research teams led by Dr. Dieter Trau, Associate Professor at the Department of Biomedical Engineering of the National University of Singapore and Co-founder of AYOXXA, and Prof. Wong Tien Yin, one of world’s top eye researchers and Medical Director at the Singapore National Eye Centre (SNEC), will closely work together during this pilot study.


Phenomenex Adds Versatile F5 (Pentafl uorophenyl) Columns With Unmatched Reproducibility to Kinetex® HPLC/UHPLC Core-Shell Line


Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, announces Kinetex F5—a robust pentafl uorophenyl propyl (PFP) core-shell phase that overcomes reproducibility and performance limitations of existing PFP and F5 products on the market. After extensive internal and external testing found that existing PFP and F5 fully porous and core-shell products produced sporadic basic compound adsorption and analyte retention time shifting, Phenomenex, in partnership with customers, redefi ned the industry standard and developed this new core-shell pentafl uorophenyl.


The new Kinetex F5 phase delivers improved reproducibility compared to other PFP or F5 columns on the market and can significantly reduce method development time with its dynamic and responsive chemical functionality. It is an ideal solution for HPLC/UHPLC development work with its combination of polar and non-polar interactions including hydrogen bonding, electrostatic, hydrophobic, aromatic, and steric/planar mechanisms. Additional versatility of this phase gives scientists the ability to use reversed phase, 2D-LC, HILIC, SFC, or even 100% aqueous separation modes. With its fluorinated groups and carbon ring structure, the Kinetex F5 is an excellent choice for both polar and non-polar compound separations as well as challenging methods that include halogenated, conjugated, or isomeric compounds.


Kinetex F5 is available in 2.6- and 1.7-µm particle sizes and delivers all the advantages of Phenomenex’s Core-Shell Technology including


www.americanpharmaceuticalreview.com | | 69


»


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76